All In Biotech

Drug Trial Radar · NCT02193620

Study of PHN131 in Patients After Surgery

A Randomized, Double Blind, Placebo-controlled, Multiple Dose Study to Assess the Efficacy, Safety and Pharmacokinetics of Oral Nalbuphine, an Oral Soft Capsule, for Post-hemorrhoidectomy Pain Management

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Apr 30, 2013

Primary completion

Sep 21, 2014

Study completion Feb 13, 2019

Sponsor

Lead sponsor
PhytoHealth CorporationIndustry
Sponsor type
Industry
First posted
Jul 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effectiveness, safety and pharmacokinetics of Oral Nalbuphine in the treatment of postoperative pain following hemorrhoidectomy.

Conditions

  • Analgesia Disorder

Interventions

  • PHN131 soft capsule with Nalbuphine HCl 60 mg/capDrug

    Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.

  • Placebo soft capsulesDrug

    Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.

  • DiclofenacDrug

    All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the area under the curve of Visual Analogue Scale (VAS) pain intensity scoresTime frame: at 1, 2, 3, 4±0.25, 8±0.5, 12±0.5, 16±0.5, 20±0.5, 24±1, 28±1, 32±2, 36±2, 40±2, 44±2, and 48±2 h after the surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Clinical Research Center, Tri-service General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.